Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA
Lynk Pharmaceuticals (Hangzhou, China) is pleased to announce exclusive licensing agreements with Kobe University (Kobe, Japan) and with RIKEN Research Institute (Saitama,... Read More
Novavax, FDB agreement for large scale manufacturing of COVID-19 vaccine candidate
Posted on28 Jul 2020
Comments0
NovavaxInc, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading CDMO for... Read More
Pfizer-BioNTech agreement with U.S. Gov for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the... Read More
Insight on Novartis’s first-of-its-kind not-for-profit medicine portfolio for symptomatic treatment of COVID-19
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major... Read More
Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based SARS-CoV-2 vaccine
Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against... Read More
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial published in The Lancet Journal
ChAdOx1 Covid-19 vaccine in clinical study The Oxford shot is one of the front runners in the vaccine race and is already... Read More
DCGI approved Itolizumab to treat COVID-19 patients with moderate to severe acute respiratory distressÂ
India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for “restricted emergency use” to treat COVID-19 patients... Read More